These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 16645086

  • 1. Neuroscience. A neuronal receptor for botulinum toxin.
    Jahn R.
    Science; 2006 Apr 28; 312(5773):540-1. PubMed ID: 16645086
    [No Abstract] [Full Text] [Related]

  • 2. SV2 is the protein receptor for botulinum neurotoxin A.
    Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER.
    Science; 2006 Apr 28; 312(5773):592-6. PubMed ID: 16543415
    [Abstract] [Full Text] [Related]

  • 3. Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition.
    Gerachshenko T, Blackmer T, Yoon EJ, Bartleson C, Hamm HE, Alford S.
    Nat Neurosci; 2005 May 28; 8(5):597-605. PubMed ID: 15834421
    [Abstract] [Full Text] [Related]

  • 4. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage.
    Sakaba T, Stein A, Jahn R, Neher E.
    Science; 2005 Jul 15; 309(5733):491-4. PubMed ID: 16020741
    [Abstract] [Full Text] [Related]

  • 5. Activity-dependent changes in partial VAMP complexes during neurotransmitter release.
    Hua SY, Charlton MP.
    Nat Neurosci; 1999 Dec 15; 2(12):1078-83. PubMed ID: 10570484
    [Abstract] [Full Text] [Related]

  • 6. [Roles of tomosyn in regulated synaptic vesicle fusion].
    Yamamoto Y, Sakisaka T.
    Tanpakushitsu Kakusan Koso; 2009 Sep 15; 54(12 Suppl):1647-53. PubMed ID: 21089602
    [No Abstract] [Full Text] [Related]

  • 7. Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses.
    Schiavo G, Stenbeck G, Rothman JE, Söllner TH.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):997-1001. PubMed ID: 9023371
    [Abstract] [Full Text] [Related]

  • 8. Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal.
    Neale EA, Bowers LM, Jia M, Bateman KE, Williamson LC.
    J Cell Biol; 1999 Dec 13; 147(6):1249-60. PubMed ID: 10601338
    [Abstract] [Full Text] [Related]

  • 9. Redistribution of presynaptic proteins during alpha-latrotoxin-induced release of neurotransmitter and membrane retrieval at the frog neuromuscular junction.
    Boudier JA, Martin-Moutot N, Boudier JL, Iborra C, Takahashi M, Seagar MJ.
    Eur J Neurosci; 1999 Oct 13; 11(10):3449-56. PubMed ID: 10564353
    [Abstract] [Full Text] [Related]

  • 10. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M, Schulze S, Strotmeier J, Mahrhold S, Richter K, Binz T, Bigalke H, Ahnert-Hilger G, Rummel A.
    Toxicon; 2013 Dec 01; 75():108-21. PubMed ID: 23817019
    [Abstract] [Full Text] [Related]

  • 11. Regulation of the synaptic vesicle cycle in Drosophila.
    Broadie KS.
    Biochem Soc Trans; 1996 Aug 01; 24(3):639-45. PubMed ID: 8878818
    [No Abstract] [Full Text] [Related]

  • 12. Alternatives to the use of animals for bacterial toxins and antitoxins.
    Sesardic D.
    Dev Biol Stand; 1999 Aug 01; 100():75-82. PubMed ID: 10616178
    [Abstract] [Full Text] [Related]

  • 13. Synaptic vesicle proteins: targets and routes for botulinum neurotoxins.
    Ahnert-Hilger G, Münster-Wandowski A, Höltje M.
    Curr Top Microbiol Immunol; 2013 Aug 01; 364():159-77. PubMed ID: 23239353
    [Abstract] [Full Text] [Related]

  • 14. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments.
    Pirazzini M, Azarnia Tehran D, Leka O, Zanetti G, Rossetto O, Montecucco C.
    Biochim Biophys Acta; 2016 Mar 01; 1858(3):467-74. PubMed ID: 26307528
    [Abstract] [Full Text] [Related]

  • 15. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals.
    Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C.
    FEBS Lett; 2013 Jan 16; 587(2):150-5. PubMed ID: 23178719
    [Abstract] [Full Text] [Related]

  • 16. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation.
    Meunier FA, Lisk G, Sesardic D, Dolly JO.
    Mol Cell Neurosci; 2003 Apr 16; 22(4):454-66. PubMed ID: 12727443
    [Abstract] [Full Text] [Related]

  • 17. Cell biology. Progress by poisoning.
    Cutler D.
    Nature; 1992 Oct 29; 359(6398):773. PubMed ID: 1436051
    [No Abstract] [Full Text] [Related]

  • 18. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
    Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, Lawrence GW, Dolly JO.
    FEBS J; 2012 Jul 29; 279(14):2555-67. PubMed ID: 22607388
    [Abstract] [Full Text] [Related]

  • 19. Dual inhibition of SNARE complex formation by tomosyn ensures controlled neurotransmitter release.
    Sakisaka T, Yamamoto Y, Mochida S, Nakamura M, Nishikawa K, Ishizaki H, Okamoto-Tanaka M, Miyoshi J, Fujiyoshi Y, Manabe T, Takai Y.
    J Cell Biol; 2008 Oct 20; 183(2):323-37. PubMed ID: 18936251
    [Abstract] [Full Text] [Related]

  • 20. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.
    Baldwin MR, Barbieri JT.
    Biochemistry; 2007 Mar 20; 46(11):3200-10. PubMed ID: 17311420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.